BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma

Bibliography

• Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968;69:537-40
   PubMed Web of Science ®Google Scholar
• Tunbridge WM, Evered DC, Hall R, The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977;7:481-93
   PubMed Web of Science ®Google Scholar
• Baldwin DB, Rowett D. Incidence of thyroid disorders in Connecticut. JAMA 1978;239:742-4
   PubMed Web of Science ®Google Scholar
• Tonacchera M, Pinchera A, Vitti P. Assessment of nodular goitre. Best Pract Res Clin Endocrinol Metab 2010;24:51-61
   PubMed Web of Science ®Google Scholar
• Ezzat S, Sarti DA, Cain DR, Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 1994;154:1838-40
   PubMed Web of Science ®Google Scholar
• Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31
   PubMed Web of Science ®Google Scholar
• Belfiore A, La Rosa GL, La Porta GA, Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992;93:363-9
   PubMed Web of Science ®Google Scholar
• Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004;351:1764-71
   PubMed Web of Science ®Google Scholar
• Kang HW, No JH, Chung JH, Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 2004;14:29-33
   PubMed Web of Science ®Google Scholar
• Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 2004;11:1093-7
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
   PubMed Web of Science ®Google Scholar
• Hamming JF, Goslings BM, van Steenis GJ, The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. Arch Intern Med 1990;150:113-16
   PubMed Web of Science ®Google Scholar
• Mandel SJ. Diagnostic use of ultrasonography in patients with nodular thyroid disease. Endocr Pract 2004;10:246-52
   PubMedGoogle Scholar
• Frates MC, Benson CB, Charboneau JW, Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794-800
   PubMed Web of Science ®Google Scholar
• Rago T, Vitti P, Chiovato L, Role of conventional ultrasonography and color flow-doppler sonography in predicting malignancy in ‘cold’ thyroid nodules. Eur J Endocrinol 1998;138:41-16
   PubMed Web of Science ®Google Scholar
• Kim EK, Park CS, Chung WY, New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 2002;178:687-91
   PubMed Web of Science ®Google Scholar
• Redman R, Zalaznick H, Mazzaferri EL, The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. Thyroid 2006;16:55-60
   PubMed Web of Science ®Google Scholar
• Ghofrani M, Beckman D, Rimm DL. The value of onsite adequacy assessment of thyroid fine-needle aspirations is a function of operator experience. Cancer 2006;108:110-13
   PubMed Web of Science ®Google Scholar
• Wang HH. Reporting thyroid fine-needle aspiration: literature review and a proposal. Diagn Cytopathol 2006;34:67-76
   PubMed Web of Science ®Google Scholar
• Poller DN, Ibrahim AK, Cummings MH, Fine-needle aspiration of the thyroid. Cancer 2000;90:239-44
   PubMed Web of Science ®Google Scholar
• British Thyroid Association, Royal College of Physicians (2007) Fine needle aspiration cytology (FNAC). In: Perros P (ed) Guidelines for the Management of Thyroid Cancer. 2nd edition. Royal College of Physicians, London: 9-10
   Google Scholar
• Baloch ZW, LiVolsi VA. Fine-needle aspiration of thyroid nodules: past, present, and future. Endocr Pract 2004;10:234-41
   PubMedGoogle Scholar
• Baloch ZW, LiVolsi VA, Asa SL, Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425-37
   PubMed Web of Science ®Google Scholar
• Raber W, Kaserer K, Niederle B, Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. Thyroid 2000;10:709-12
   PubMed Web of Science ®Google Scholar
• Yoder BJ, Redman R, Massoll NA. Validation of a five-tier cytodiagnostic system for thyroid fine needle aspiration biopsies using cytohistologic correlation. Thyroid 2006;16:781-6
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-85
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010;399:313-17
   PubMed Web of Science ®Google Scholar
• Marais R, Light Y, Paterson HF, Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997;272:4378-83
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6
   PubMed Web of Science ®Google Scholar
• Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-44
   PubMed Web of Science ®Google Scholar
• Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 2009;8:1168-75
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Fratev F, Jonsdottir SO. The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study. J Mol Graph Model 2010;28:598-603
   PubMed Web of Science ®Google Scholar
• Moretti S, De Falco V, Tamburrino A, Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. Biochim Biophys Acta 2009;1793:1634-45
   PubMed Web of Science ®Google Scholar
• Brummer T, Martin P, Herzog S, Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene 2006;25:6262-76
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-19
   PubMed Web of Science ®Google Scholar
• Ciampi R, Knauf JA, Kerler R, Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005;115:94-101
   PubMed Web of Science ®Google Scholar
• Hou P, Liu D, Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007;6:377-9
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9
   PubMed Web of Science ®Google Scholar
• Santarpia L, Sherman SI, Marabotti A, Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 2009;40:827-33
   PubMed Web of Science ®Google Scholar
• Trovisco V, Vieira de Castro I, Soares P, BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202:247-51
   PubMed Web of Science ®Google Scholar
• Kim SK, Hwang TS, Yoo YB, Surgical results of thyroid nodules according to a management guideline based on the BRAFV600E mutation status. J Clin Endocrinol Metab 2011;96:658-64
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62
   PubMed Web of Science ®Google Scholar
• Cameselle-Teijeiro J, Abdulkader I, Perez-Becerra R, BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor lesion? Hum Pathol 2009;40:1029-35
   PubMed Web of Science ®Google Scholar
• Chung KW, Yang SK, Lee GK, Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006;65:660-6
   PubMed Web of Science ®Google Scholar
• Sebastian SO, Gonzalez JM, Paricio PP, Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg 2000;135:272-7
   PubMed Web of Science ®Google Scholar
• Lang BH, Lo CY, Chan WF, Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 2006;30:752-8
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62
   PubMed Web of Science ®Google Scholar
• Sheu SY, Vogel E, Worm K, Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Histopathology 2010;56:632-40
   PubMed Web of Science ®Google Scholar
• Trovisco V, Soares P, Preto A, Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005;446:589-95
   PubMed Web of Science ®Google Scholar
• Rodolico V, Cabibi D, Pizzolanti G, BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer 2007;110:1218-26
   PubMed Web of Science ®Google Scholar
• Kim TY, Kim WB, Song JY, The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63:588-93
   PubMed Web of Science ®Google Scholar
• Park YJ, Kim YA, Lee YJ, Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 2009;32:38-45
   Web of Science ®Google Scholar
• Basolo F, Torregrossa L, Giannini R, Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 2010;95:4197-205
   PubMed Web of Science ®Google Scholar
• Ugolini C, Giannini R, Lupi C, Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007;17:381-8
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Rowland JM, Bove KE, Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-4
   PubMed Web of Science ®Google Scholar
• Thomas GA, Bunnell H, Cook HA, High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 1999;84:4232-8
   PubMed Web of Science ®Google Scholar
• Lima J, Trovisco V, Soares P, BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4267-71
   PubMed Web of Science ®Google Scholar
• Collins BJ, Schneider AB, Prinz RA, Low frequency of BRAF mutations in adult patients with papillary thyroid cancers following childhood radiation exposure. Thyroid 2006;16:61-6
   PubMed Web of Science ®Google Scholar
• Powell N, Jeremiah S, Morishita M, Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 2005;205:558-64
   PubMed Web of Science ®Google Scholar
• Soares P, Trovisco V, Rocha AS, BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-80
   PubMed Web of Science ®Google Scholar
• Sapio MR, Posca D, Troncone G, Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006;154:341-8
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Kimura ET, Gandhi M, BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404
   PubMed Web of Science ®Google Scholar
• Hayashida N, Namba H, Kumagai A, A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 2004;14:910-15
   PubMed Web of Science ®Google Scholar
• Jin L, Sebo TJ, Nakamura N, BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006;15:136-43
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Trasforini G, Leoni S, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009;161:467-73
   PubMed Web of Science ®Google Scholar
• Xing M, Tufano RP, Tufaro AP, Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89:2867-72
   PubMed Web of Science ®Google Scholar
• Chuang TC, Chuang AY, Poeta L, Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 2009;32:229-34
   Web of Science ®Google Scholar
• Kwak JY, Kim EK, Kim JK, Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. Head Neck 2010;32:490-8
   PubMed Web of Science ®Google Scholar
• Kim SW, Lee JI, Kim JW, BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010;95:3693-700
   PubMed Web of Science ®Google Scholar
• Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998;281:363-5
   PubMed Web of Science ®Google Scholar
• Jo YS, Huang S, Kim YJ, Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf) 2009;70:139-44
   PubMed Web of Science ®Google Scholar
• Zhu Z, Ciampi R, Nikiforova MN, Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006;91:3603-10
   PubMed Web of Science ®Google Scholar
• Rosai J, Caracangiu ML, DeLellis RA. Atlas of tumor pathology: tumors of the thyroid gland, 3rd series. Armed Forces Institute of Pathology; Washington DC: 1992, 247-58
   Google Scholar
• Cohen Y, Rosenbaum E, Clark DP, Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10:2761-5
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM, Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-8
   PubMed Web of Science ®Google Scholar
• Spencer CA, Bergoglio LM, Kazarosyan M, Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-75
   PubMed Web of Science ®Google Scholar
• Vdovichenko KK, Markova SI, Belokhvostov AS. Mutant form of BRAF gene in blood plasma of cancer patients. Ann N Y Acad Sci 2004;1022:228-31
   PubMed Web of Science ®Google Scholar
• Yancovitz M, Yoon J, Mikhail M, Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 2007;9:178-83
   PubMed Web of Science ®Google Scholar
• Cradic KW, Milosevic D, Rosenberg AM, Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 2009;94:5001-9
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38-46
   PubMed Web of Science ®Google Scholar
• Frasca F, Nucera C, Pellegriti G, BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008;15:191-205
   PubMed Web of Science ®Google Scholar
• Wang Y, Ji M, Wang W, Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 2008;15:183-90
   PubMed Web of Science ®Google Scholar
• Kebebew E, Weng J, Bauer J, The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-70; discussion 470-1
   PubMed Web of Science ®Google Scholar
• Lupi C, Giannini R, Ugolini C, Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-90
   PubMed Web of Science ®Google Scholar
• Ito Y, Yoshida H, Maruo R, BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009;56:89-97
   PubMed Web of Science ®Google Scholar
• Elisei R, Ugolini C, Viola D, BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-9
   PubMed Web of Science ®Google Scholar
• Michels JJ, Jacques M, Henry-Amar M, Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007;38:212-19
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Leboeuf R, Patel KN, Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 2007;17:655-61
   PubMed Web of Science ®Google Scholar
• Xing M, Clark D, Guan H, BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009;27:2977-82
   PubMed Web of Science ®Google Scholar
• Trovisco V, Soares P, Sobrinho-Simoes M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006;37:781-6
   PubMed Web of Science ®Google Scholar
• Soares P, Sobrinho-Simoes M. Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer? Future Oncol 2009;5:1225-9
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Tseng GC, Steward D, MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-8
   PubMed Web of Science ®Google Scholar
• Cantara S, Capezzone M, Marchisotta S, Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2009;95:1365-9
   Web of Science ®Google Scholar
• Hisham AN, Azlina AF, Aina EN, Total thyroidectomy: the procedure of choice for multinodular goitre. Eur J Surg 2001;167:403-5
   PubMedGoogle Scholar
• Snook KL, Stalberg PL, Sidhu SB, Recurrence after total thyroidectomy for benign multinodular goiter. World J Surg 2007;31:593-8; discussion 599-600
   PubMed Web of Science ®Google Scholar
• Musholt TJ, Fottner C, Weber MM, Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg 2010;34:2595-603
   PubMed Web of Science ®Google Scholar
• Castro P, Rebocho AP, Soares RJ, PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:213-20
   PubMed Web of Science ®Google Scholar
• Sapio MR, Guerra A, Posca D, Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 2007;14:1089-97
   PubMed Web of Science ®Google Scholar
• Sapio MR, Posca D, Raggioli A, Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 2007;66:678-83
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42
   PubMed Web of Science ®Google Scholar
• Kim KH, Kang DW, Kim SH, Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-21
   PubMed Web of Science ®Google Scholar
• Frattini M, Ferrario C, Bressan P, Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-40
   PubMed Web of Science ®Google Scholar
• Fugazzola L, Mannavola D, Cirello V, BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239-43
   PubMed Web of Science ®Google Scholar
• Puxeddu E, Moretti S, Elisei R, BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-20
   PubMed Web of Science ®Google Scholar
• Salvatore G, Giannini R, Faviana P, Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004;89:5175-80
   PubMed Web of Science ®Google Scholar
• Fugazzola L, Puxeddu E, Avenia N, Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455-64
   PubMed Web of Science ®Google Scholar
• Girlando S, Cuorvo LV, Bonzanini M, High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy. Int J Surg Pathol 2010;18:173-6
   PubMed Web of Science ®Google Scholar
• Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006;13:257-69
   PubMed Web of Science ®Google Scholar
• Giannini R, Ugolini C, Lupi C, The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3511-16
   PubMed Web of Science ®Google Scholar
• Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009;115:972-80
   PubMed Web of Science ®Google Scholar
• Abubaker J, Jehan Z, Bavi P, Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008;93:611-18
   PubMed Web of Science ®Google Scholar
• Kim SK, Kim DL, Han HS, Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008;17:118-25
   PubMed Web of Science ®Google Scholar